文献库搜索 | GeneLibs

Liu(X),Chen(W),Xin(C),Wang(Z),Yi(K),Wang(L... Health Sci Rep 2026-05-00

...PIK3CA, STK11, ERBB2, BRAF, CTNNB1, MET, and PTEN. Enrichment analysis indicated that these genetic alterations were pri...

Taher(D),Khalil(B),AlNaimat(S),Mustafa(M),... RSC Adv 2026-04-29

...PIK3CA-E545K, ERBB4-Y1242C, KRAS-G13D, PIK3CA-H1047R, and ATM-A112V) identified meta- and para-substituted analogues (4b...

Shi(Y),Zhang(Y),Liu(D),Xiang(S),Liang(S),L... J Ethnopharmacol 2026-08-10

...PIK3CA as direct binding targets of DIO, which was further validated by cellular thermal shift assay (CETSA). Consistent...

Wei(L),El-Naggar(AM),Li(Y),Ding(Y),Li(E),L... BMC Cancer 2026-05-04

...PIK3CA mutations that drive PI3K/AKT/mTOR signaling and HIF1α expression. Despite their clinical success in some cancers...

Kubiak(K),Bidzińska(J),Bednarek(M),Szurows... Diagnostics (Basel) 2026-04-16

...PIK3CA mutations, HER2 amplification, BRCA1/2 pathogenic variants, and NTRK fusions, each linked to approved therapeutic...

Quagliariello(V),Berretta(M),Barbato(M),Ma... Int J Mol Sci 2026-04-17

Activating PIK3CA mutations occur in approximately 40% of hormone receptor-positive (HR+)/HER2-negative breast cancers a...

Onar(LC),Guner(E),Yilmaz(I) J Clin Med 2026-04-10

...PIK3CA, SRC, MAPK1, and MAPK3) significantly enriched in PI3K/AKT, MAPK/ERK, and ErbB signaling pathways. Conclusions: C...

Ugbaja(SC),Nkabinde(SA),Nkabinde(M),Gqalen... Pharmaceuticals (Basel) 2026-04-16

...PIK3CA, PIK3CB, PIK3R1, and PTPN11). Gene Ontology and KEGG pathway enrichment were performed with an FDR cut-off < 0.05...

Tang(M),Sallavanti(J),Lanza(M),Covington(D... PLoS One None

Vascular malformations are anomalies of blood or lymphatic vessels that are frequently associated with activating PIK3CA...

Whaley(RD),Gupta(S),Erickson(LA) Hum Pathol 2026-08-00

...PIK3CA. In this limited series only one patient died of disease. Even so, three were alive with disease at distant metas...